This clinical trial is focused on studying a condition known as Relapsing Multiple Sclerosis (RMS). RMS is a type of multiple sclerosis where patients experience episodes of new or worsening symptoms, known as relapses, followed by periods of recovery. The study aims to evaluate the effectiveness and safety of a medication called Fenebrutinib compared to another medication called Teriflunomide. Fenebrutinib is taken in the form of film-coated tablets and is being tested to see how well it works in reducing the frequency of relapses in patients with RMS.

Participants in the study will be randomly assigned to receive either Fenebrutinib, Teriflunomide, or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drugs being tested. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The trial will last for a period of time during which participants will take the medication orally, and their health will be monitored regularly to assess the impact of the treatment on their condition.

The main goal of the study is to determine how well Fenebrutinib works in reducing the annualized relapse rate, which is the average number of relapses a patient experiences in a year. Additionally, the study will look at other factors such as changes in brain volume, the number of new or enlarging lesions detected by MRI scans, and any side effects experienced by participants. This research is important for understanding the potential benefits and risks of Fenebrutinib as a treatment option for people living with RMS.